Tuberculosis Treatment Compounds with Enhanced Solubility
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current tuberculosis therapies are lengthy, complex, and ineffective against emerging resistant strains of Mycobacterium tuberculosis, including multi-drug resistant and extensively drug resistant TB, necessitating the development of new agents that can shorten treatment duration and combat resistant mutants.
Innovation Solution
Development of compounds represented by the general formula (I) or their pharmaceutically acceptable salts, which include specific functional groups and structures that enhance solubility and efficacy against Mycobacterium tuberculosis and other resistant mycobacterial infections, potentially used in conjunction with existing anti-mycobacterial agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current anti-TB drugs (isoniazide and rifampin) are used, then treatment effectiveness against susceptible strains is maintained, but treatment duration becomes excessively long and complexity increases
Solution Approach 1:
The patent modifies the chemical structure of existing anti-TB drugs by introducing new substituents and functional groups (such as fluorine atoms, different ring structures, and side chain variations) to create compounds with improved pharmacokinetic properties. These structural parameter changes aim to enhance bacterial killing efficiency while reducing the required treatment duration.
Solution Approach 2:
The patent develops composite molecular structures that combine elements of existing anti-TB agents with novel chemical moieties. These hybrid compounds integrate the proven efficacy of traditional drugs with new functional groups designed to overcome resistance mechanisms and improve drug penetration, thereby shortening treatment courses.
2Adaptability or versatility
If current anti-TB therapies are used, then standard TB strains are treated, but emerging resistant mutants including multi-drug resistant and extensively drug resistant TB remain ineffective
Solution Approach 1:
The patent introduces specific functional groups and chemical modifications at particular positions on the molecular core structure. These localized changes are designed to interact with specific resistance mechanisms in Mycobacterium tuberculosis, allowing the drug to maintain effectiveness against resistant strains while preserving activity against susceptible strains.
Solution Approach 2:
The patent designs compounds that specifically target resistance mechanisms. By understanding how resistant strains modify their cellular targets or efflux pumps, the invention creates molecules that exploit these resistance mechanisms rather than being blocked by them, converting the bacteria's defensive adaptations into vulnerabilities.
3Ease of operation
If therapy complexity is reduced, then patient compliance improves, but treatment effectiveness against resistant strains may be compromised
Solution Approach 1:
The patent develops single compounds that can address multiple resistance mechanisms simultaneously. These multi-functional molecules are designed to inhibit several bacterial enzymes or pathways involved in drug resistance, allowing simplified monotherapy or reduced combination regimens to maintain effectiveness against diverse resistant strains.
Data Source
AI summary
The present invention provides compounds for the treatment of a bacterial infection. Additionally, the present invention provides compositions and methods for using these compounds and compositions in the treatment of a bacterial infection in a subject.